排名前五的靶点	数量

DYRK1A(双特异性酪氨酸-磷酸化调控激酶-1A)	3
HDACs(组蛋白去乙酰化酶家族)	3
EZH2(组蛋白赖氨酸甲基化酶EZH2)	2
DNA	2
EphA2(A型肝配蛋白受体-2)	1

关联

项与台北医学大学相关的药物

Artenimol

双氢青蒿素

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1997-01-01

Imofinostat

靶点

HDACs

作用机制

HDAC抑制剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

Fucoidan

褐藻多糖硫酸酯

靶点

CLEC-2 x CTNNB

作用机制

CLEC-2 agonists [+1]

在研机构

台北医学大学 [+2]

原研机构

南京医科大学第一附属医院

在研适应症

幽门螺杆菌感染 [+3]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

361

项与台北医学大学相关的临床试验

NCT06930313

/ Not yet recruitingN/AIIT

Development and Evaluation of a Brief Compassion-Based Intervention for Managing Depression and Anxiety in Family Caregivers of Lung Cancer Patients: A Mixed Methods Randomized Controlled Trial

Objectives: This 3-year study aims to develop, refine, and evaluate a brief compassion-based intervention specifically designed for family caregivers of lung cancer patients. In the first year, the primary focus will be on developing the intervention content and assessing its feasibility and acceptability. In the second and third years, the goal will be to assess the intervention's effects on depression and anxiety.
Method: In the first year, the intervention will be developed in three stages. Initially, the intervention will be created based on compassion-focused theory and evidence-based exercises, incorporating feedback from family caregivers in previous studies and insights from professionals to ensure its relevance to lung cancer caregivers. Next, a pilot study will test the intervention's feasibility and acceptability with 30 family caregivers, using mixed methods to gather session-by-session feedback and assess recruitment, retention, and adherence. Following the pilot, the intervention will be revised based on participant and researcher feedback, preparing it for further study. In the second and third years, a randomized controlled trial (RCT) will be conducted with 84 participants randomly assigned to either the 4-session Brief Compassion-Based Intervention (BCI) or a single-session Telephone-Based Support and Education (TSE) control group. Outcomes, including depression, anxiety, caregiver stress, mindfulness, self-compassion, and self-efficacy, will be measured at baseline, immediately post-intervention, and at 3- and 6-month follow-ups. For data analysis, long-term follow-up quantitative data will be analyzed using the Generalized Estimating Equation (GEE) to examine group differences. Moderation and mediation analyses will be conducted to explore potential moderators and mechanisms of the intervention. Qualitative data from interviews will be analyzed using content analysis.
Expected Results: This study is expected to provide a comprehensive understanding of the feasibility, acceptability, and effectiveness of compassion-based interventions for lung cancer caregivers, contributing to their application in clinical care practice.

开始日期2026-03-01

申办/合作机构

台北医学大学

[+1]

NCT06487650

/ Not yet recruitingN/AIIT

The Development and Evaluation of Sleep Intervention for Perinatal Family

Background: Sleep disruptions and disturbances are highly prevalent among new mothers and fathers and negatively affect their mental health and infant development outcomes. Effective sleep interventions are vital for family health.
Objectives: To develop a sleep intervention for mother-father-infant triads, and to evaluate the effects on sleep improvement, emotional distress, and infant health outcomes.
Methods: In this proposal, we plan to conduct a parallel-group two-arm randomized controlled trial on pregnant women and their partners. Mother-father-infant triads will be recruited and randomly allocated to the intervention group (receiving a sleep intervention) or the control group. Data will be collected with repeated measures, and the relationship between studied variables will be analyzed with descriptive and inferential statistics.
Anticipatory results: The development and evaluation of an evidence-based sleep intervention will provide a scientific insight into sleep care for pregnant women and their families.

开始日期2025-12-01

申办/合作机构

台北医学大学

NCT07044492

/ Not yet recruitingN/AIIT

The Effectiveness of Empathy-Based Program on Empathy Level Among Nursing Assistants in Long-term Care Facility

This randomized controlled trial aims to explore the impact of an Empathy-Based Program on the level of empathy among nursing assistants in a long-term care facility. A total of 100 participants will be divided into two groups: a virtual reality (VR) with debriefing group, and a control group (C) receiving routine care. The intervention involves a weekly 5-minute VR session featuring immersive experiences of residents' lives within the facility, followed by a 25-minute debriefing discussion in small groups of 5
6 participants. This will continue for three weeks. The study will evaluate the effectiveness of the empathy program in enhancing nursing assistants' empathy levels, with data collection occurring at three time points: baseline, post-intervention, and one-month follow-up.

开始日期2025-09-01

申办/合作机构

台北医学大学

100 项与台北医学大学相关的临床结果

登录后查看更多信息

0 项与台北医学大学相关的专利（医药）

登录后查看更多信息

23,171

项与台北医学大学相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Impact of PM _2.5 , relative humidity, and temperature on sleep quality: a cross-sectional study in Taipei

Article

作者: Chang, Jer-Hwa ; Lee, Yueh-Lun ; Xuan Thao, Huynh Nguyen ; Ba Dung, Hoang ; Thanh Tung, Nguyen ; Lin, Yuan-Chien ; Thi Hien, Nguyen ; Tsai, Cheng-Yu ; Lo, Kang ; Phan Chung Thuy, Tran ; Ho, Kin Fai ; Liu, Wen-Te ; Lo, Chen-Chen ; Chuang, Hsiao-Chi ; Chuang, Kai-Jen ; Viet Trung, Lam

INTRODUCTION:

TWe investigated impacts of particulate matter with an aerodynamic diameter of less than 2.5 μm (PM_2.5), relative humidity (RH), and temperature on sleep stages and arousal.

MATERIALS AND METHODS:

A cross-sectional analysis involving 8,611 participants was conducted at a sleep center in Taipei. We estimated individual-level exposure to RH, temperature, and PM_2.5 over 1-day, 7-day, and 30-day periods. Linear regression models assessed the relationship between these environmental factors and sleep parameters across different seasons. Mediation analysis was used to explore PM_2.5, RH, and temperature roles in these relationships.

RESULTS:

A 1% increase in RH over 1 and 7 days was associated with changes in non-rapid eye movement (NREM) sleep stages and increases in the arousal index across all seasons. A 1°C increase in temperature over similar periods led to increases in rapid eye movement (REM) sleep. During cold season, changes in RH and temperature were linked to variations in arousal and NREM sleep stages. In hot season, RH and temperature increases were correlated with changes in NREM sleep stages and arousal. Across all groups, a 1-μg/m³ increase in PM_2.5 levels was associated with alterations in NREM and REM sleep stages and increases in the arousal index. We found PM_2.5 levels mediated relationships between RH, temperature, and various sleep stages, particularly in cold season.

CONCLUSIONS:

Lower RH and temperature, contributing to deep sleep reduction and increased arousal, were influenced by elevated PM_2.5 exposure, especially during colder months. Enhancing environmental quality and reducing PM_2.5 levels may lead to improved sleep quality.

2025-12-31·ANNALS OF MEDICINE

Combination of reverse shock index and simplified motor score as a strong discriminator of trauma outcomes

Article

作者: Ma, Hon-Ping ; Wu, Meng-Yu ; Chung, Jui-Yuan ; Lin, Mau-Roung ; Yiang, Giou-Teng ; Chen, Sy-Jou ; Chu, Chi-Ming ; Chien, Ding-Kuo

BACKGROUND:

The reverse shock index multiplied by simplified motor score (rSI-sMS) is a novel and rapid measure for assessing injury severity in patients with trauma in prehospital settings; however, its discriminant ability requires further validation.

METHODS:

A retrospective cohort study was conducted from trauma database of Taipei Tzu Chi Hospital to compare the accuracy of the rSI-sMS with that of the shock index, modified shock index, reverse shock index multiplied by the Glasgow Coma Scale (rSI-GCS), and the reverse shock index multiplied by GCS motor subscale (rSI-GCSM) for discriminating in-hospital mortality, intensive care unit (ICU) admissions, prolonged ICU stays ≥14 days, and prolonged hospital stays ≥30 days in patients with trauma.

RESULTS:

A total of 11,760 patients from the trauma database were included. rSI-sMS had significantly better accuracy in discriminating in-hospital mortality, ICU admissions, prolonged ICU stays (≥14 days), and prolonged hospital stays (≥30 days) than the shock index, modified shock index, and rSI-GCSM, whereas its accuracy was similar to that of the rSI-GCS. Furthermore, rSI-sMS had better accuracy for discriminating clinical outcomes in patients with an injury severity score (ISS) ≥16, motor vehicle collisions, falls, no chronic disease, and cardiovascular disease as well as in geriatric and nongeriatric patients. In patients with mixed and isolated brain injuries, rSI-sMS accurately discriminated the four clinical outcomes, similar to rSI-GCS. The optimal cutoff value of rSI-sMS had a discriminant ability of 85.0, 78.6, 75.2, and 81.0% for in-hospital mortality, ICU admissions, ICU stay ≥14 days, and hospital stays of ≥30 days, respectively.

CONCLUSIONS:

Compared with the shock index, modified shock index, and rSI-GCSM, rSI-sMS is a more accurate field triage scoring system for discriminating in-hospital mortality, ICU admissions, prolonged ICU stay, and prolonged hospital stays in patients with trauma.

2025-12-31·SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Rapid isolation of extracellular vesicles from stem cell conditioned medium using osmosis-driven filtration

Article

作者: Lundy, David J ; Lai, James J ; Nguyen, Helen ; Huang, Casey Y

Extracellular vesicles (EVs) hold significant promise as biomarkers and therapeutics, yet their isolation remains challenging due to their low abundance and complex sample matrices. Here, we introduce EV-Osmoprocessor (EVOs), a novel device that leverages osmosis-driven filtration for rapid and efficient EV isolation. EVOs employs a high osmolarity polymer solution to concentrate EVs while simultaneously removing smaller contaminants. Compared to traditional methods such as ultracentrifugation and precipitation, EVOs offers speed and convenience, achieving a 50-fold volume reduction in under 2 h. Our results show that EVOs retained EVs and removed >99% albumin from the cell conditioned culture medium (CCM). The isolated EVs exhibited a particle size distribution centered around 140 nm, which was very similar to EVs isolated via precipitation or ultracentrifugation. The standalone EVOs process achieved a particle:protein ratio (EV purity) of ~10⁷ particles/µg protein. Comprehensive characterization, including cryo-electron microscopy, validation of protein markers and known miRNA cargo confirmed the successful isolation of EVs. Functional assays, based on protection of cardiomyocytes from hypoxia/reoxygenation injury, demonstrated the bioactivity of EVOs-isolated EVs. Furthermore, we show that EVOs can be used to concentrate 30 ml of CCM into a 0.5 ml solution, which was then further processed with size-exclusion chromatography (SEC), improving EV purity to ~10⁹ particles/µg protein. This work establishes EVOs as a promising tool for EV research and clinical applications, offering a streamlined approach to EV isolation with enhanced analytical performance.

项与台北医学大学相关的新闻（医药）

2025-07-13

·奇点网

JNCI：二甲双胍又填空白！中国科学家首次发现，炎症性肠病患者服用二甲双胍，与患肠癌风险降低56%相关

*仅供医学专业人士阅读参考已经有不少研究发现，糖尿病患者使用二甲双胍，与患结直肠癌风险较低相关。那如果这些2型糖尿病患者又多一项肠癌风险因素呢？例如，同时患有炎症性肠病。服用二甲双胍与肠癌风险较低之间的相关性，还会存在吗？近日，由我国台北医学大学、中山医学大学和辅仁大学的研究人员组成的研究团队，在著名期刊Journal of the National Cancer Institute上发表了一篇重要研究成果[1]，填补了上述空白。他们基于我国台湾省匹配的1695名使用二甲双胍的炎症性肠病患者与1695名未使用者数据，发现二甲双胍的使用与结直肠癌风险降低56％相关（aHR=0.44），与全因死亡率降低32％相关（aHR=0.68）。而且结直肠癌风险随着累积暴露剂量的增加而下降；累积剂量最高的四分位组风险降低了67％（aHR=0.33）。研究人员基于一个囊括了241590名年龄在20岁及以上的炎症性肠病患者数据库中，进行了倾向评分匹配（PSM），分别筛选了1695名使用二甲双胍的炎症性肠病患者，和相匹配的1695名未使用者二甲双胍的炎症性肠病患者。两组受试者的基线特征均衡良好，平均年龄相近（56.99岁 vs 56.45岁），且约70%的研究对象年龄在51岁以上。在时间依赖性Cox模型分析中，二甲双胍使用与结直肠癌风险降低56%显著相关（aHR=0.44；P=0.0002），还与全因死亡率降低32%显著相关（aHR=0.68；P<0.00001）。这些相关性在所有调整模型中均保持稳定。他们也进行了结直肠癌特异性死亡风险的事后分析。虽然肠癌相关死亡事件的数量有限，但是在所有模型中，二甲双胍的使用仍与较低的肠癌特异性死亡率显著相关。在模型4中，二甲双胍的使用与肠癌特异性死亡风险降低44%相关（aHR=0.56；P=0.0172）。此外，他们还发现累积二甲双胍暴露量与肠癌风险之间存在显著的剂量-反应关系。与最低四分位数（Q1）相比，最高三个四分位数（Q2、Q3和Q4）的完全校正后aHR分别为0.68（Q2）、0.57（Q3）和0.33（Q4），趋势检验具有统计学意义（趋势P值<0.001）。显然，暴露量越高，患肠癌的风险降低越多，最高可降低67%。总的来说，我国研究人员的这项研究成果表明，对于身患炎症性肠病的成人而言，二甲双胍的使用与肠癌风险显著降低有关，而且这种相关性还存在剂量-反应关系。据了解，这也是科学家首次在炎症性肠病患者群体中发现，服用二甲双胍与肠癌风险降低有关。需要指出的是，这一研究结果仍需前瞻性随机研究验证，在临床试验证实上述发现之前，不建议炎症性肠病患者自行服用二甲双胍预防肠癌。参考文献：[1].Huang YJ, Lin JA, Chen WM, Shia BC, Wu SY. Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, Population-Based cohort study. J Natl Cancer Inst. Published online July 2, 2025. doi:10.1093/jnci/djaf165本文作者丨BioTalker

临床结果AHA会议

2025-07-01

·ioncology

ESMO GI 2025明日启幕，中国消化道肿瘤前沿声音响彻巴塞罗那

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA）、2项微型口头报告（MO）、1项教育主题汇报（Education Session）和34篇壁报（Poster）。现将中国之声整理如下，以飨读者。最新突破性摘要（LBA）摘要号：LBA1研究名称：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND TrialFIND试验中期分析：ctDNA甲基化动态监测指导非转移性结直肠癌术后随访讲者：彭俊杰 | 复旦大学附属肿瘤医院会场：Room Madrid时间：7月4日 16:30 - 16:40（当地时间）摘要号：LBA2研究名称：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)TALENTACE研究：比较按需TACE联合阿替利珠单抗+贝伐珠单抗(Atezo+Bev)与单纯按需TACE治疗未经系统治疗的中高肿瘤负荷不可切除肝细胞癌（uHCC）的III期开放标签随机对照研究讲者：韩国宏 | 西安国际医学中心医院会场：Room Barcelona时间：7月3日 14:50 - 15:00（当地时间）微型口头报告（Mini Oral）摘要号：149MO研究名称：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 StudyABSK-011-201研究II期最新结果：依帕戈替尼（ABSK-011）联合阿替利珠单抗用于FGF19过表达型晚期肝细胞癌（HCC）的一线治疗及用于经免疫检查点抑制剂（ICIs）治疗患者的疗效分析讲者：程琪 | 华中科技大学同济医学院附属同济医院会场：Room Barcelona时间：7月2日 17:15 - 17:20（当地时间）摘要号：150MO研究名称：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosisSIERRA研究IIIb期安全性分析：度伐利尤单抗（D）联合替西木单抗（T）一线治疗伴临床预后不良特征的肝细胞癌（HCC）患者讲者：Stephen L. Chan | 香港中文大学会场：Room Barcelona时间：7月2日 17:20 - 17:25（当地时间）教育专题会（Education Session）讲题：New medical treatment in 2025 beyond IO combinations2025年突破免疫联合疗法的新兴医学治疗方向讲者：Stephen L. Chan | 香港中文大学会场：Room Madrid时间：7月3日 12:00 - 12:20（当地时间）壁报（Poster）01结直肠癌摘要号：11P研究名称：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I StudyNALIRIFOX联合靶向治疗一线治疗转移性结直肠癌的I期研究讲者：Haojie Zhou | 复旦大学附属中山医院摘要号：49P研究名称：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer转移性结直肠癌一线诱导治疗后维持策略与治疗间歇的多中心倾向性评分匹配比较研究讲者：Ka Yan Lai | 伊利沙伯医院摘要号：65P研究名称：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal CancerBETTER研究：替雷利珠单抗+贝伐珠单抗+TAS102+SBRT三线治疗MSS/pMMR转移性结直肠癌的开放标签单臂试验讲者：张群 | 南京鼓楼医院摘要号：98P研究名称：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth一种预测早期结直肠癌浸润深度的整合分子标志物的新型风险分层模型讲者：Bing Li | 复旦大学附属中山医院摘要号：130eP研究名称：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer从循证到实践：MSS/MSI-L结直肠癌免疫治疗的多中心真实世界研究与Meta分析讲者：Yue T. Gou | 中南大学湘雅医院摘要号：131eP研究名称：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment贝伐珠单抗+奥沙利铂+伊立替康三联方案治疗氟尿嘧啶经治转移性结直肠癌的疗效与安全性讲者：韩璐 | 中国人民解放军总医院第五医学中心摘要号：139eP研究名称：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)中国结直肠癌MSI/MMR检测与治疗实践全国调研（SUMMER研究）讲者：王正航 | 北京大学肿瘤医院摘要号：146TiP研究名称：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progressMIRACLE3研究：依沃西单抗联合放化疗一线治疗MSS型不可切除肝/肺转移结直肠癌的II期试验（进行中）讲者：李心翔 | 复旦大学附属肿瘤医院摘要号：224P研究名称：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)SPRING-01研究：短程放疗序贯信迪利单抗+CAPOX全直肠新辅助治疗局部进展期直肠癌的前瞻性随机对照试验讲者：田锋 | 山东第一医科大学附属省立医院摘要号：226P研究名称：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results阿得贝利单抗+短程放疗+CAPOX全新辅助治疗pMMR局部进展期直肠癌的中期分析讲者：靖昌庆 | 山东第一医科大学附属省立医院摘要号：229P研究名称：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)高风险局部进展期直肠癌新辅助放化疗±FOLFOXIRI强化治疗的随机研究：临床与生存质量分析（NCT03997435）讲者：Ka Yan Lai | 伊利沙伯医院02肝胆胰肿瘤摘要号：157P研究名称：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analysesCheckMate 9DW研究拓展分析：纳武利尤单抗联合伊匹木单抗 vs 仑伐替尼或索拉非尼一线治疗中国不可切除/晚期肝细胞癌患者讲者：秦叔逵 | 中国药科大学附属南京天印山医院摘要号：183P研究名称：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population中性粒细胞-淋巴细胞比值（NLR）与PLR、LMR、SII、PNI在肝癌冷冻消融术患者中的预后价值比较及最佳适用人群探索讲者：李家平 | 中山大学附属第一医院摘要号：195P研究名称：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinomaCOVID-19、肝硬化与肝细胞癌关联机制的生物信息学与系统生物学研究讲者：Xianxiang Chen | 广西医科大学第一附属医院摘要号：203eP研究名称：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis基于cfDNA生物标志物与人工智能模型的肝癌早期筛查：系统评价与Meta分析讲者：Minh Le | 台北医学大学摘要号：206eP研究名称：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib基线ALBI分级对接受仑伐替尼治疗的肝细胞癌患者预后的影响讲者：商昌珍 | 中山大学孙逸仙纪念医院摘要号：209eP研究名称：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT MechanismRPL41通过转录因子RUNX2介导的上皮间质转化（EMT）机制促进肝细胞癌转移讲者：Zheng A. Hua | 重庆大学附属沙坪坝医院摘要号：302P研究名称：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer索凡替尼联合吉西他滨及白蛋白结合型紫杉醇用于可切除/临界可切除胰腺癌新辅助治疗讲者：高松 | 天津市肿瘤医院摘要号：313P研究名称：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancerABHD17C介导的BCL6B蛋白S-去棕榈酰化通过激活CD24转录抵抗胰腺癌巨噬细胞吞噬讲者：Yalu Zhang | 中国科学技术大学附属第一医院摘要号：317P研究名称：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity肿瘤微环境芯片：异质性下免疫治疗疗效的实时观测窗口讲者：Chiao-Min Lin | 台湾清华大学摘要号：358P研究名称：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study胆道癌根治术后辅助化疗方案的疗效比较：单中心回顾性队列研究讲者：Wen-Ying Lin | 台北荣民总医院03胃食管癌摘要号：394P研究名称：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials卡瑞利珠单抗为基础治疗食管鳞癌的反应性皮肤毛细血管内皮增生（RCCEP）：两项III期试验的合并分析讲者：骆卉妍 | 中山大学肿瘤防治中心摘要号：396P研究名称：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy卡博替尼联合阿替利珠单抗用于含铂化疗失败的复发/转移性食管鳞癌（R/M ESCC）患者：单臂II期研究讲者：Hung-Yang Kuo | 台湾大学医学院附设医院摘要号：399P研究名称：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic ReprogrammingARL5B通过ROCK1-SREBP1介导代谢重编程驱动食管鳞癌进展的机制研究讲者：Xinyue Ma | 山东大学齐鲁医院摘要号：418P研究名称：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study纳武利尤单抗一线治疗晚期胃/胃食管结合部腺癌的真实世界研究结局：多中心回顾性观察研究讲者：邱红 | 华中科技大学同济医学院附属同济医院摘要号：419P研究名称：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)SURPASS研究：中国晚期胃/胃食管结合部癌（GC/GEJC）真实世界治疗模式与生物标志物检测现状调研讲者：Rongrui Liu | 中国人民解放军总医院摘要号：424P研究名称：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study化疗（SOX）联合替雷利珠单抗治疗胃癌肝转移：一项多中心II期研究的首次报告讲者：康牧星 | 浙江大学医学院附属第二医院摘要号：430P研究名称：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical TrialCLDN18.2特异性CAR-T细胞（CT041）治疗胃癌的应答与耐药特征解析：I期临床试验探索性生物标志物分析讲者：彭浩欣 | 北京大学肿瘤医院摘要号：436P研究名称：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions肝切除改善原发性病灶切除的胃癌肝转移患者预后讲者：Yun Feng | 复旦大学附属肿瘤医院04其他摘要号：219eP研究名称：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study转移性胃肠间质瘤行肿瘤细胞减灭术的预后因素分析：一项回顾性队列研究讲者：Haidong Zhang | 四川大学华西医院摘要号：495P研究名称：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction初始剂量减量策略改善老年胃肠道肿瘤患者化疗耐受性的优化研究讲者：Wendy W. Chan | 香港玛丽医院摘要号：499P研究名称：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapyTACR1基因型与含奥氮平止吐方案防治化疗相关性呕吐的疗效关联研究讲者：Winnie Yeo | 香港中文大学摘要号：505eP研究名称：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers安罗替尼治疗贝伐珠单抗经治胃肠道肿瘤的真实世界疗效讲者：陈锦章 | 南方医科大学南方医院摘要号：506eP研究名称：Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study基于CARG评估指导抗肿瘤治疗剂量调整对中国老年癌症患者不良事件的影响：前瞻性研究讲者：葛郁平 | 北京协和医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期免疫疗法临床结果

2025-07-01

·肿瘤界

2025 ESMO GI | 中国智慧闪耀国际：入选研究一览

点击蓝字关注我们前言一年一度的欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于2025年7月2日~5日在巴塞罗那召开。日前，大会官网披露了摘要标题，其中34项中国研究入选。整理如下，和您一起先睹为快！胃食管癌1摘要号：394P研究名称（英文）：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials 讲者：骆卉妍 | 中山大学肿瘤防治中心2摘要号：396P研究名称（英文）：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy 讲者：Hung-Yang Kuo | 台湾大学医学院附设医院3摘要号：399P研究名称（英文）：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming 讲者：Xinyue Ma | 山东大学齐鲁医院4摘要号：418P研究名称（英文）：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study 讲者：邱红 | 华中科技大学同济医学院附属同济医院5摘要号：419P研究名称（英文）：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)讲者：Rongrui Liu | 中国人民解放军总医院6摘要号：424P研究名称（英文）：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study 讲者：康牧星 | 浙江大学医学院附属第二医院7摘要号：430P研究名称（英文）：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial 讲者：彭昊昕 | 北京大学肿瘤医院8摘要号：436P研究名称（英文）：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions讲者：Yun Feng | 复旦大学附属肿瘤医院肝胆胰肿瘤1摘要号：LBA2研究名称（英文）：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) 讲者：韩国宏 | 西安国际医学中心医院2摘要号：149MO研究名称（英文）：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study讲者：程琪 | 华中科技大学同济医学院附属同济医院3摘要号：150MO研究名称（英文）：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis讲者：Stephen L. Chan | 香港中文大学4摘要号：157P研究名称（英文）：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses 讲者：秦叔逵 | 中国药科大学附属南京天印山医院5摘要号：183P研究名称（英文）：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population讲者：李家平 | 中山大学附属第一医院6摘要号：195P研究名称（英文）：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma讲者：Xianxiang Chen | 广西医科大学第一附属医院7摘要号：203eP研究名称（英文）：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis讲者：Minh Le | 台北医学大学8摘要号：206eP研究名称（英文）：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib讲者：商昌珍 | 中山大学孙逸仙纪念医院9摘要号：209eP研究名称（英文）：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism讲者：Zheng Hua | 重庆大学附属沙坪坝医院10摘要号：302P研究名称（英文）：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer讲者：高松 | 天津市肿瘤医院11摘要号：313P研究名称（英文）：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer讲者：Yalu Zhang | 中国科学技术大学附属第一医院12摘要号：317P研究名称（英文）：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity讲者：Chiao-Min Lin | 台湾清华大学13摘要号：358P研究名称（英文）：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study讲者：Wen-Ying Lin | 台北荣民总医院结直肠癌1摘要号：LBA1研究名称（英文）：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial讲者：彭俊杰 | 复旦大学附属肿瘤医院2摘要号：11P研究名称（英文）：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study讲者：Haojie Zhou | 复旦大学附属中山医院3摘要号：49P研究名称（英文）：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer讲者：Connie Ka Yan Lai | 伊利沙伯医院4摘要号：65P研究名称（英文）：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer 讲者：张群 | 南京鼓楼医院5摘要号：98P研究名称（英文）：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth讲者：Bing Li | 复旦大学6摘要号：130eP研究名称（英文）：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer讲者：Yue Gou | 中南大学7摘要号：131eP研究名称（英文）：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment讲者：韩璐 | 中国人民解放军总医院第五医学中心8摘要号：139eP研究名称（英文）：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)讲者：王正航 | 北京大学肿瘤医院9摘要号：146TiP研究名称（英文）：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress讲者：李心翔 | 复旦大学附属肿瘤医院10摘要号：224P研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)讲者：Feng Tian | 山东第一医科大学附属省立医院11摘要号：226P研究名称（英文）：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results讲者：靖昌庆 | 山东第一医科大学附属省立医院12摘要号：229P研究名称（英文）：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)讲者：Ka Yan Lai | 伊利沙伯医院胃肠道罕见肿瘤1摘要号：219eP研究名称（英文）：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study 讲者：Haidong Zhang | 四川大学华西医院其他1摘要号：495P研究名称（英文）：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction讲者：Wendy W. Chan | 香港大学李嘉诚医学院2摘要号：499P研究名称（英文）：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy讲者：Winnie Yeo | 香港中文大学3摘要号：505eP研究名称（英文）：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers讲者：陈锦章 | 南方医科大学南方医院备注：如有遗漏或任何问题，请给我们留言~声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：lagertha审核：南星

临床结果细胞疗法临床2期免疫疗法

100 项与台北医学大学相关的药物交易

登录后查看更多信息

100 项与台北医学大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月09日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Anti-CEACAM HCAb-ADC(Taipei Medical University) ( CEACAM6 )	结直肠癌更多	临床前
NSC361563 ( DYRK1A )	阿尔茨海默症更多	临床前
AptBCis2 ( DNA )	恶病质更多	临床前
3-Monothiopomamalomide	神经炎性疾病更多	临床前
BA-5 ( LPS x TGF-β1 )	肝细胞癌更多	临床前